PDS Biotechnology Corp (NASDAQ: PDSB) is a clinical-stage biopharmaceutical company that develops immunology-based cancer therapies and infectious disease vaccines. The company has generated no revenue from commercial product sales as of the 10-K filed March 30, 2026. PDS Biotech funds operations through equity issuances, including at-the-market common stock programs and warrant offerings, while pursuing potential future revenue from research and development payments, product royalties, license fees, and milestone payments. The company operates two cationic lipid-based platform technologies: Versamune, applied to cancer immunotherapy candidates, and Infectimune, applied to infectious disease vaccine candidates including a universal influenza program. PDS Biotech is incorporated and files tax returns in New Jersey and at the U.S. federal level. The company has accumulated a deficit and relies on external capital to fund ongoing clinical development activities.

Revenue model

No commercial revenue as of the FY2025 10-K filed March 30, 2026. The company finances operations through equity capital markets, including at-the-market common stock issuances, stock option exercises, and warrant offerings. Potential future revenue streams cited in the filing include R&D payments, product royalties, license fees, upfront payments, and clinical milestone payments, none of which had been realized as of the filing date.

Products and services

Versamune: cationic lipid-based platform for cancer immunotherapy product candidates. Infectimune: cationic lipid-based platform for infectious disease vaccines, including PDS0202, a universal influenza vaccine candidate with preclinical data presented in January 2022. Both platforms are in development stages with no approved or commercialized products as of the filing date.

Customers and end markets

No commercial customers as of the 10-K filed March 30, 2026. Target end markets are oncology and infectious disease. Future customers would include hospitals, health systems, and insurers subject to FDA approval and reimbursement coverage decisions.

Value-chain role

Preclinical and clinical-stage drug developer. The company outsources clinical trial execution and manufacturing to contract research organizations and contract manufacturers. Internal capabilities focus on platform technology development, regulatory strategy, and clinical program management.

Geographic exposure

U.S.-focused operations. Files U.S. federal and New Jersey state income tax returns. No material international revenue or operations disclosed in the filing excerpts.

Source: SEC 10-K, filed 2026-03-30

Industry: Pharmaceutical Preparations Peers: Axcella Health Inc. GELESIS HOLDINGS, INC. Fortress Biotech Inc Cue Biopharma, Inc. Cypherpunk Technologies Inc HCW Biologics Inc Longeveron Inc Palvella Therapeutics Inc SPECTRUM PHARMACEUTICALS INC